Derivative Valuation Loss of 94.9 Billion Won, 42.73% of Equity
-
Derivative valuation loss of 94,851,602,803 won (42.73% of equity of 221,976,975,980 won)
-
Accounting loss due to fair value increase of conversion and redemption rights on convertible bonds (non-cash)
-
Upon conversion, the derivative loss is expected to transfer to capital, improving financial structure
-
Loss date: March 31, 2026
-
Unaudited internal settlement data, subject to change
KOSDAQ Filing Information
-
Filing: Occurrence Of Loss On Derivative Transactions
-
Company: Kolon TissueGene (950160)
-
Submission: Kolon TissueGene, Inc.
-
Receipt: 05-15-2026
-
Under KRX KOSDAQ Market Division